«This study shows that undifferentiated iPS cells are rejected by the immune system upon transplantation in the same recipient, but that fully differentiating these cells allows for acceptance and tolerance by the immune system without the
need for immunosuppression.»
In particular, there have been no serious, unexpected, adverse events related to AST - OPC1, the injection procedure, or the drug
used for immunosuppression in any of the 30 subjects.
Rapamycin is a drug currently
approved for immunosuppression during preparatory and maintenance regimens for organ and bone marrow transplant in human patients.
A biolimb would get round many of these obstacles as it only contains cells from the recipient so would avoid the
need for immunosuppression.